Insight Brief

How Immune Repertoire Sequencing Advances Immuno-oncology Biomarker Development Programs

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

With the ability to test on small sample amounts, immune repertoire profiling provides an effective way to assess the changes taking place in a patient’s immune system throughout the disease progression and therapeutic intervention.

Learn from our genomics and immunology experts as they examine 5 key considerations when incorporating B cell/T cell repertoire profiling in your clinical trial studies; and, the advantages and disadvantages of 3 current leading technologies for biomarker analysis – flow cytometry, next-generation sequencing and immunohistochemistry.

Contact us to learn how we can advance your immuno-oncology drug development program.


More Resources

Fighting Cancer: How Biomarker Testing and 3 Key Research Tools Shape Immunotherapy Drug Development
Proven Benefits of Gene Expression Profiling for Biomarker Discovery in Immunotherapy Trials
How Flow Cytometry Advances Immuno-oncology Clinical Trial Studies
View All